The US Food and Drug Administration (US FDA) has completed an inspection of Eugia Pharma Specialities Ltd.’s Unit III, a formulation manufacturing facility, concluding on February 6, 2026. Eugia Pharma is a wholly owned subsidiary of Aurobindo Pharma. The inspection resulted in 11 observations, which are procedural in nature. The company is committed to addressing these observations within the stipulated timeframe.
Inspection Overview
The United States Food and Drug Administration (US FDA) concluded its inspection of Unit III, a formulation manufacturing facility belonging to Eugia Pharma Specialities Ltd., a wholly owned subsidiary of Aurobindo Pharma. The facility is located in Pashamylaram, Telangana.
Inspection Details
The inspection took place from January 27 to February 6, 2026. At the conclusion of the inspection, there were a total of 11 observations.
Nature of Observations and Company Response
The observations noted during the US FDA inspection are procedural in nature. Aurobindo Pharma has stated that it will respond to the observations within the specified timeframe.
Commitment to Quality
Aurobindo Pharma is dedicated to upholding high-quality manufacturing standards across all its facilities. The company has committed to keeping the stock exchanges informed regarding any further information related to the inspection.
Impact Assessment
The company believes the inspection will not impact their financial performance or operations.
Source: BSE
